Mackay Shields LLC’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mackay Shields LLC’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,735	Closed	-$2.36M	–	1183
2021 Q1	$2.36M	Sell	20,735 -12,836	-38%	-$1.75M	0.02%	699
2020 Q4	$4.65M	Sell	33,571 -4,500	-12%	-$534K	0.03%	506
2020 Q3	$3.13M	Sell	38,071 -5,100	-12%	-$423K	0.02%	597
2020 Q2	$3.38M	Buy	43,171 +3,200	+8%	+$212K	0.03%	526
2020 Q1	$1.77M	Sell	39,971 -6,400	-14%	-$332K	0.02%	714
2019 Q4	$1.98M	Sell	46,371 -600	-1%	-$24.8K	0.01%	878
2019 Q3	$2.01M	Sell	46,971 -800	-2%	-$43.5K	0.01%	899
2019 Q2	$3.03M	Buy	47,771 +30,836	+182%	+$1.96M	0.02%	753
2019 Q1	$1.17M	Buy	16,935 +1,300	+8%	+$74.3K	0.01%	945
2018 Q4	$679K	Sell	15,635 -1,663	-10%	-$90.9K	0.01%	1061
2018 Q3	$1.32M	Buy	17,298 +1,900	+12%	+$155K	0.01%	815
2018 Q2	$1.18M	Sell	15,398 -300	-2%	-$19.4K	0.01%	907
2018 Q1	$800K	Buy	+15,698	New	+$791K	0.01%	1030

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Mackay Shields LLC's RARE Position: Q2 2021 in Review

Mackay Shields LLC sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 20,735 shares — an estimated $2.36M sold.

Mackay Shields LLC first reported a position in RARE in Q1 2018 and held it in 13 quarters. The position peaked at $4.65M in Q4 2020. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Mackay Shields LLC reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Mackay Shields LLC sold 20,735 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $2.36M.
Mackay Shields LLC first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 13 quarters.
Mackay Shields LLC's Ultragenyx Pharmaceutical position peaked at $4.65M in Q4 2020.
242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.